GlassScriptPhysician profile
George N Thomas
NPI 1861836033
$8,552.74
in general payments reported to CMS, 2019-2025
24 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.94 · 2020: $144 · 2021: $624 · 2022: $951 · 2023: $856 · 2024: $5,572 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,250 · Food and Beverage: $1,569 · Travel and Lodging: $926 · Education: $43.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,250.00 |
| Food and Beverage | $1,569.03 |
| Travel and Lodging | $926.00 |
| Education | $43.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,705.42 | 2021-2025 | Botox, Ubrelvy, Vraylar |
| Aurinia Pharma U.S., INC. | $218.99 | 2021-2023 | Lupkynis |
| Pfizer INC. | $211.69 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.76 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $198.32 | 2022-2025 | |
| Novo Nordisk INC | $105.21 | 2022-2025 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $102.75 | 2022-2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $96.32 | 2022-2023 | Korsuva, Velphoro |
| Upsher-Smith Laboratories LLC | $88.69 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $87.66 | 2020-2025 | |
| Glaxosmithkline, LLC. | $84.71 | 2023-2024 | Trelegy Ellipta, Arexvy, Benlysta |
| Lilly USA, LLC | $80.91 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $71.83 | 2022-2023 | Rayaldee |
| Amgen INC. | $51.16 | 2021-2022 | |
| Vifor Pharma, INC. | $40.69 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.77 | 2021-2024 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $32.47 | 2022 | |
| Allergan, INC. | $24.91 | 2020 | |
| Calliditas Therapeutics US INC. | $24.04 | 2022 | |
| Renalytix Ai, INC. | $20.12 | 2022 | |
| Melinta Therapeutics, LLC | $19.69 | 2021 | |
| Amicus Therapeutics, INC. | $17.33 | 2022 | |
| Gilead Sciences, INC. | $14.50 | 2023 | Veklury |
| Eisai INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.